Akebia Therapeutics prices upsized IPO at $17, the high end of the range

Shutterstock photo

Akebia Therapeutics, a biotech developing a breakthrough anemia treatment with a once-daily oral dose, raised $100 million in an upsized IPO by offering 5.9 million shares at $17, the high end of the range of $14 to $17. The company had originally planned to offer 4.9 million shares. Akebia Therapeutics plans to list on the NASDAQ under the symbol AKBA. Akebia Therapeutics initially filed confidentially on 12/20/2013. Morgan Stanley, Credit Suisse and UBS Investment Bank acted as lead managers on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs
Referenced Symbols: AKBA

More from Renaissance Capital


Renaissance Capital

Renaissance Capital


Research Brokers before you trade

Want to trade FX?